Orange Book product · Generic (ANDA)
LACOSAMIDE
LACOSAMIDE
At a glance
Mar 17, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 17, 2022
4 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
LACOSAMIDE
Strength
50MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 208308
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LACOSAMIDE
- 2023MOTPOLY XRBrand (NDA)
NDA 216185 · AUCTA
- 2010VIMPATBrand (NDA)
NDA 022255 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022254 · UCB INC
- 2008VIMPATBrand (NDA)
NDA 022253 · UCB INC
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220366 · STERANCO HLTHCARE
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220386 · REGCON HOLDINGS
- 2026LACOSAMIDEGeneric (ANDA)
ANDA 220268 · GLENMARK PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 219699 · AJENAT PHARMS
- 2025LACOSAMIDEGeneric (ANDA)
ANDA 218706 · WESTMINSTER PHARMS
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 218464 · ACELLA
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 214960 · SOMERSET THERAPS LLC
- 2024LACOSAMIDEGeneric (ANDA)
ANDA 213109 · UNICHEM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
